What Revaree Plus is
Revaree Plus is a hormone-free vaginal insert containing 10 mg of hyaluronic acid, with sweet almond oil and glycerides. It is sold by Bonafide and made by Farma-Derma, the company that holds the FDA clearance. It is meant to be used on a regular schedule rather than at the time of sex. FDA cleared it through the 510(k) process as "Revaree Plus Vaginal Suppositories" (FDA 510(k) K213220). The device classification is "Lubricant, Personal" (FDA product classification NUC). So it is regulated as a personal lubricant device, not as a drug, even though it is marketed and used as a moisturizer. It was not tested for condom compatibility, and FDA's record lists it as not compatible with natural rubber latex, polyurethane and polyisoprene condoms.
Hyaluronic acid trial evidence
A PubMed search found no published trials of Revaree Plus itself. Most of the evidence is for vaginal hyaluronic acid as a class.
- A 2026 meta-analysis of randomized trials found that, in three placebo-controlled trials, vaginal hyaluronic acid improved dryness-related quality of life and sexual function compared with placebo. The evidence was rated moderate certainty for those outcomes, and no serious adverse events were reported PMID: 41773428. The authors called for more standardized formulations and longer studies.
- In a 49-woman randomized pilot trial funded by Bonafide, a 5 mg hyaluronic acid insert used twice weekly and estradiol vaginal cream (an FDA-approved prescription product, e.g. Estrace (estradiol) cream — DailyMed Drug Label) showed no meaningful difference over 12 weeks PMID: 39042017. The full text does not name the product; it describes the insert as 5 mg of hyaluronic acid in semi-synthetic glycerides and cites FDA's Revaree Plus record (pilot trial full text). Revaree Plus contains 10 mg per its 510(k) summary, so the dose tested matches original Revaree. It was small, recruited at one center and not blinded.
- In a 53-woman trial in the menopausal transition, a hyaluronic acid gel added no benefit over a polycarbophil gel. That trial was small and open-label, and two of its authors listed a pharmaceutical company affiliation PMID: 35131532.
Placebo-controlled class evidence earns Revaree Plus a grade of B here. Its price lowers the rating by 0.2, to 3.6 overall. That is still above Replens (3.0), because hyaluronic acid has stronger placebo-controlled evidence, but Revaree Plus costs several times as much per use.
Is Revaree Plus worth the price?
Consider Revaree Plus if you want a hormone-free option backed by placebo-controlled trials of its ingredient, and the monthly cost is manageable.
Consider Replens if cost matters. A polycarbophil gel performed similarly in one small head-to-head trial.
See a clinician if symptoms are moderate to severe or do not improve, or if you have any bleeding after menopause. The North American Menopause Society recommends prescription options such as low-dose vaginal estrogen (FDA-approved; Vagifem (estradiol) — DailyMed Drug Label) for moderate to severe symptoms PMID: 32852449. Our guide to vaginal dryness during menopause compares moisturizers with vaginal estrogen.